

**ADOCIA**

innovative medicine  
for everyone, everywhere



## PRESS RELEASE

### **Adocia: modification of the means allocated to the liquidity agreement**

**Lyon, France, February 10, 2015** - Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a modification of the means allocated to its liquidity agreement as of February 10, 2015.

According to the terms of the liquidity agreement entered into with Kepler Capital Markets SA on May 19, 2014, Adocia decided to proceed to a partial withdrawal of the funds allocated to this agreement for an amount of EUR 700,000.

It is reminded that, according to the authorization granted by the last general shareholders meeting dated June 24, 2014, the maximum purchase price per share (excluding charges and commissions) under this liquidity agreement amounts to EUR 50.

#### **About Adocia**

##### ***To be a global leader in the innovative delivery of insulins and therapeutic proteins***

ADOCIA is a clinical stage biotechnology company that specializes in the development of innovative formulations of already approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. ADOCIA's proprietary BioChaperone<sup>®</sup> technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

In December 2014, ADOCIA signed a partnership with the company Eli Lilly for the development and commercialization of its new formulation of insulin lispro, BioChaperone Lispro, previously tested successfully in two phase Ib/IIa studies.

ADOCIA will continue to develop its fast-acting human insulin formulation internally. ADOCIA is also actively continuing the development of its BioChaperone Combo, a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. A dose-response clinical study (Phase IIa) is scheduled for the first quarter of 2015.

Besides, in August 2014, ADOCIA launched a phase III clinical study in India on its product based on PDGF-BB for treatment of the diabetic foot ulcer (BioChaperone PDGF-BB).

ADOCIA has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). ADOCIA is engaged in collaborative programs with two major pharmaceutical companies in this field.

***Fighting cancer with targeted treatments***

DriveIn<sup>®</sup> is a nanotechnology which is intended to significantly improve delivery of active compounds into cancer cells. This new proprietary platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

***« Innovative medicine for everyone, everywhere »***

ADOCIA's therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

ADOCIA is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index.

American Depositary Receipts representing ADOCIA common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit: [www.adocia.com](http://www.adocia.com)

**Contact ADOCIA**

G rard Soula - [contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)

Chairman and CEO of ADOCIA

Tel.: +33 4 72 610 610



**Press Relations**

**ALIZE RP**

Caroline Carmagnol

[caroline@alizerp.com](mailto:caroline@alizerp.com)

[adocia@alizerp.com](mailto:adocia@alizerp.com)

Tel.: + 33 1 44 54 36 61